open access
The assessment of plasma visfatin concentration in patients with metabolic syndrome and essential hypertension
open access
Abstract
Material and methods Sixty eight patients were qualified for the study and divided into: group 1 - with metabolic syndrome and hypertension (n = 31), group 2 - with essential hypertension (n = 22), group 3 - control group (n = 15). In all subjects we measured: anthropometric measurements, blood pressure values, fat tissue mass, lipid and glycemic profile. Oral glucose tolerance test (OGTT) and insulin-resistance ratio were estimated. Fasting and postprandial visfatin was measured using ELISA method.
Results Mean plasma fasting visfatin in 3 groups was respectively: group 1 - 1.58 ± 1.88 ng/ml, group 2 - 0.82 ± 0.87 ng/ml, group 3 - 1.69 ± 1.58 ng/ml. Mean postprandial plasma visfatin levels in studied groups was respectively: group 1 - 1.36 ± 1.35 ng/ml, group 2 - 0.63 ± 0.44 ng/ml, group 3 - 0.70 ± 0.32 ng/ml. Significant differences were found in group 1 v. 2 and 3. Fasting plasma visfatin correlated with waist circumference and mean diastolic blood pressure value. No significant linear correlation were found between fasting plasma visfatin and insulin-resistance ratio (IRI/G), fat tissue mass, body mass index, triglicerides, HDL cholesterol and OB. No linear relationship was found between plasma visfatin and glucose level.
Conclusions Visfatin may have impact on modulation of hypertension values. There is no relationship between serum visfatin level, insulin- resistance ratio and fat tissue mass despite positive correlation with waist circumference therefore visfatin can not be indicated as a link between obesity and insulin-resistance or as a predictive factor for diabetes type 2 development.
Abstract
Material and methods Sixty eight patients were qualified for the study and divided into: group 1 - with metabolic syndrome and hypertension (n = 31), group 2 - with essential hypertension (n = 22), group 3 - control group (n = 15). In all subjects we measured: anthropometric measurements, blood pressure values, fat tissue mass, lipid and glycemic profile. Oral glucose tolerance test (OGTT) and insulin-resistance ratio were estimated. Fasting and postprandial visfatin was measured using ELISA method.
Results Mean plasma fasting visfatin in 3 groups was respectively: group 1 - 1.58 ± 1.88 ng/ml, group 2 - 0.82 ± 0.87 ng/ml, group 3 - 1.69 ± 1.58 ng/ml. Mean postprandial plasma visfatin levels in studied groups was respectively: group 1 - 1.36 ± 1.35 ng/ml, group 2 - 0.63 ± 0.44 ng/ml, group 3 - 0.70 ± 0.32 ng/ml. Significant differences were found in group 1 v. 2 and 3. Fasting plasma visfatin correlated with waist circumference and mean diastolic blood pressure value. No significant linear correlation were found between fasting plasma visfatin and insulin-resistance ratio (IRI/G), fat tissue mass, body mass index, triglicerides, HDL cholesterol and OB. No linear relationship was found between plasma visfatin and glucose level.
Conclusions Visfatin may have impact on modulation of hypertension values. There is no relationship between serum visfatin level, insulin- resistance ratio and fat tissue mass despite positive correlation with waist circumference therefore visfatin can not be indicated as a link between obesity and insulin-resistance or as a predictive factor for diabetes type 2 development.
Keywords
visfatin; metabolic syndrome; hypertension; visceral fat tissue
Title
The assessment of plasma visfatin concentration in patients with metabolic syndrome and essential hypertension
Journal
Issue
Article type
Original paper
Pages
258-265
Published online
2009-07-21
Page views
644
Article views/downloads
1747
Bibliographic record
Nadciśnienie tętnicze 2009;13(4):258-265.
Keywords
visfatin
metabolic syndrome
hypertension
visceral fat tissue
Authors
Joanna Foremska-Iciek
Karolina Hoffmann
Danuta Pupek-Musialik